185 related articles for article (PubMed ID: 21623171)
1. Inhibition of Aurora-A kinase induces cell cycle arrest in epithelial ovarian cancer stem cells by affecting NFĸB pathway.
Chefetz I; Holmberg JC; Alvero AB; Visintin I; Mor G
Cell Cycle; 2011 Jul; 10(13):2206-14. PubMed ID: 21623171
[TBL] [Abstract][Full Text] [Related]
2. Preclinical evaluation of the Aurora kinase inhibitors AMG 900, AZD1152-HQPA, and MK-5108 on SW-872 and 93T449 human liposarcoma cells.
Noronha S; Alt LAC; Scimeca TE; Zarou O; Obrzut J; Zanotti B; Hayward EA; Pillai A; Mathur S; Rojas J; Salamah R; Chandar N; Fay MJ
In Vitro Cell Dev Biol Anim; 2018 Jan; 54(1):71-84. PubMed ID: 29197031
[TBL] [Abstract][Full Text] [Related]
3. Regulation of inflammation by the NF-κB pathway in ovarian cancer stem cells.
Leizer AL; Alvero AB; Fu HH; Holmberg JC; Cheng YC; Silasi DA; Rutherford T; Mor G
Am J Reprod Immunol; 2011 Apr; 65(4):438-47. PubMed ID: 20825380
[TBL] [Abstract][Full Text] [Related]
4. MK-5108, a highly selective Aurora-A kinase inhibitor, shows antitumor activity alone and in combination with docetaxel.
Shimomura T; Hasako S; Nakatsuru Y; Mita T; Ichikawa K; Kodera T; Sakai T; Nambu T; Miyamoto M; Takahashi I; Miki S; Kawanishi N; Ohkubo M; Kotani H; Iwasawa Y
Mol Cancer Ther; 2010 Jan; 9(1):157-66. PubMed ID: 20053775
[TBL] [Abstract][Full Text] [Related]
5. NSAID-activated gene 1 mediates pro-inflammatory signaling activation and paclitaxel chemoresistance in type I human epithelial ovarian cancer stem-like cells.
Kim KH; Park SH; Do KH; Kim J; Choi KU; Moon Y
Oncotarget; 2016 Nov; 7(44):72148-72166. PubMed ID: 27708225
[TBL] [Abstract][Full Text] [Related]
6. Response of experimental malignant melanoma models to the pan-Aurora kinase inhibitor VE-465.
Pirker C; Lötsch D; Spiegl-Kreinecker S; Jantscher F; Sutterlüty H; Micksche M; Grusch M; Berger W
Exp Dermatol; 2010 Dec; 19(12):1040-7. PubMed ID: 21087322
[TBL] [Abstract][Full Text] [Related]
7. Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth.
Lin YG; Immaneni A; Merritt WM; Mangala LS; Kim SW; Shahzad MM; Tsang YT; Armaiz-Pena GN; Lu C; Kamat AA; Han LY; Spannuth WA; Nick AM; Landen CN; Wong KK; Gray MJ; Coleman RL; Bodurka DC; Brinkley WR; Sood AK
Clin Cancer Res; 2008 Sep; 14(17):5437-46. PubMed ID: 18765535
[TBL] [Abstract][Full Text] [Related]
8. Co-inhibition of polo-like kinase 1 and Aurora kinases promotes mitotic catastrophe.
Li J; Hong MJ; Chow JP; Man WY; Mak JP; Ma HT; Poon RY
Oncotarget; 2015 Apr; 6(11):9327-40. PubMed ID: 25871386
[TBL] [Abstract][Full Text] [Related]
9. Comparing Aurora A and Aurora B as molecular targets for growth inhibition of pancreatic cancer cells.
Warner SL; Munoz RM; Stafford P; Koller E; Hurley LH; Von Hoff DD; Han H
Mol Cancer Ther; 2006 Oct; 5(10):2450-8. PubMed ID: 17041088
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression.
Deng J; Bai X; Feng X; Ni J; Beretov J; Graham P; Li Y
BMC Cancer; 2019 Jun; 19(1):618. PubMed ID: 31234823
[TBL] [Abstract][Full Text] [Related]
11. TLR2 enhances ovarian cancer stem cell self-renewal and promotes tumor repair and recurrence.
Chefetz I; Alvero AB; Holmberg JC; Lebowitz N; Craveiro V; Yang-Hartwich Y; Yin G; Squillace L; Gurrea Soteras M; Aldo P; Mor G
Cell Cycle; 2013 Feb; 12(3):511-21. PubMed ID: 23324344
[TBL] [Abstract][Full Text] [Related]
12. Aurora-A induces cell survival and chemoresistance by activation of Akt through a p53-dependent manner in ovarian cancer cells.
Yang H; He L; Kruk P; Nicosia SV; Cheng JQ
Int J Cancer; 2006 Nov; 119(10):2304-12. PubMed ID: 16894566
[TBL] [Abstract][Full Text] [Related]
13. Aurora-a is essential for the tumorigenic capacity and chemoresistance of colorectal cancer stem cells.
Cammareri P; Scopelliti A; Todaro M; Eterno V; Francescangeli F; Moyer MP; Agrusa A; Dieli F; Zeuner A; Stassi G
Cancer Res; 2010 Jun; 70(11):4655-65. PubMed ID: 20460511
[TBL] [Abstract][Full Text] [Related]
14. Aurora kinase A promotes ovarian tumorigenesis through dysregulation of the cell cycle and suppression of BRCA2.
Yang G; Chang B; Yang F; Guo X; Cai KQ; Xiao XS; Wang H; Sen S; Hung MC; Mills GB; Chang S; Multani AS; Mercado-Uribe I; Liu J
Clin Cancer Res; 2010 Jun; 16(12):3171-81. PubMed ID: 20423983
[TBL] [Abstract][Full Text] [Related]
15. The induction of polyploidy or apoptosis by the Aurora A kinase inhibitor MK8745 is p53-dependent.
Nair JS; Ho AL; Schwartz GK
Cell Cycle; 2012 Feb; 11(4):807-17. PubMed ID: 22293494
[TBL] [Abstract][Full Text] [Related]
16. ALDH1A1-related stemness in high-grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR-PI3K/aurora kinase inhibitors.
Kaipio K; Chen P; Roering P; Huhtinen K; Mikkonen P; Östling P; Lehtinen L; Mansuri N; Korpela T; Potdar S; Hynninen J; Auranen A; Grénman S; Wennerberg K; Hautaniemi S; Carpén O
J Pathol; 2020 Feb; 250(2):159-169. PubMed ID: 31595974
[TBL] [Abstract][Full Text] [Related]
17. Nuclear orphan receptor NR2F6 confers cisplatin resistance in epithelial ovarian cancer cells by activating the Notch3 signaling pathway.
Li H; Zhang W; Niu C; Lin C; Wu X; Jian Y; Li Y; Ye L; Dai Y; Ouyang Y; Chen J; Qiu J; Song L; Zhang Y
Int J Cancer; 2019 Oct; 145(7):1921-1934. PubMed ID: 30895619
[TBL] [Abstract][Full Text] [Related]
18. Galectin-3 regulates metastatic capabilities and chemotherapy sensitivity in epithelial ovarian carcinoma via NF-κB pathway.
Lu H; Liu Y; Wang D; Wang L; Zhou H; Xu G; Xie L; Wu M; Lin Z; Yu Y; Li G
Tumour Biol; 2016 Aug; 37(8):11469-77. PubMed ID: 27012551
[TBL] [Abstract][Full Text] [Related]
19. Inhibiting the aurora B kinase potently suppresses repopulation during fractionated irradiation of human lung cancer cell lines.
Sak A; Stuschke M; Groneberg M; Kübler D; Pöttgen C; Eberhardt WE
Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):492-9. PubMed ID: 22381900
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of Aurora A by loss of CHFR gene expression increases the growth and survival of HTLV-1-infected T cells through enhanced NF-kappaB activity.
Tomita M; Toyota M; Ishikawa C; Nakazato T; Okudaira T; Matsuda T; Uchihara JN; Taira N; Ohshiro K; Senba M; Tanaka Y; Ohshima K; Saya H; Tokino T; Mori N
Int J Cancer; 2009 Jun; 124(11):2607-15. PubMed ID: 19230025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
